New Standard of Care for High-Risk Smoldering Multiple Myeloma: Insights from ASH 2024

IMF Chief Medical Officer Dr. Joseph Mikhael takes a deeper dive into the groundbreaking research presented at the American Society of Hematology (ASH) annual meeting, highlighting the AQUILA Clinical Trial's promising findings on high-risk smoldering multiple myeloma. This study demonstrates how early intervention with single-agent daratumumab can delay disease progression and improve survival rates. Discover the trial's key insights, the significance of timely treatment decisions, and earlier use of CAR T-cell therapy. _______________ Improving Lives | Finding the Cure Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy. Subscribe to our channel:    / imfmyeloma   Visit our website at: https://www.myeloma.org Find us online: Facebook: @myeloma |   / myeloma   X/Twitter: @IMFMyeloma |   / imfmyeloma   Instagram: @imfmyeloma |   / imfmyeloma   LinkedIn:   / international-myeloma-foundation   Support the IMF | Donate Now! https://fundraise.myeloma.org/give/52... Category Nonprofits & Activism License Standard YouTube License In most cases, captions are autogenerated by YouTube.